Related Experiment Video
Updated: Jul 2, 2026
08:45
New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Thrombocytopenia in liver disease
Edoardo G Giannini1, Vincenzo Savarino
1Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genova, Italy. egiannini@unige.it
Current Opinion in Hematology
|August 13, 2008
Summary
Thrombocytopenia in chronic liver disease is complex, with new therapies like eltrombopag showing promise for increasing platelet counts. Treating low platelets may offer clinical benefits, but its impact on liver disease coagulopathy requires further study.
Area of Science:
- Hepatology
- Hematology
- Immunology
Background:
- Thrombocytopenia is a common complication in chronic liver disease (CLD).
- Understanding its complex pathophysiology is crucial for effective management.
- Existing treatments have limitations and varying efficacy.
Purpose of the Study:
- To review recent findings on the pathophysiology of thrombocytopenia in CLD.
- To evaluate current and emerging therapeutic strategies.
- To assess the clinical implications of these advancements.
Main Methods:
- Literature review of recent studies on CLD-associated thrombocytopenia.
- Analysis of pathophysiological mechanisms, including antibody relevance.
- Evaluation of therapeutic interventions such as splenectomy, embolization, and pharmacological agents.
Main Results:
- Antiplatelet antibodies have minimal impact on thrombocytopenia in viral liver disease.
- Eltrombopag safely increases platelet counts in viral liver disease patients, enabling antiviral therapy.
- Splenectomy and splenic embolization remain therapeutic options, with patient selection critical for embolization success.
Conclusions:
- Novel insights into thrombocytopenia pathophysiology in CLD offer clinical potential.
- Emerging therapies, particularly eltrombopag, show promise for managing low platelet counts.
- Further research is needed to determine if treating thrombocytopenia improves liver disease-associated coagulopathy.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...